Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
geraniin
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Geraniin is a prominent hydrolyzable tannin, specifically an ellagitannin, characterized by its dehydrohexahydroxydiphenoyl (DHHDP) group. It is naturally found in various plants, including *Geranium thunbergii* and *Acer pseudosieboldianum*. Geraniin has demonstrated significant biological activities, including anti-oxidative, anti-inflammatory, and anti-proliferative effects. In oncological research, particularly concerning prostate cancer, geraniin has been shown to inhibit cell proliferation and induce apoptosis. Its mechanism of action involves the inhibition of DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b), which facilitates the demethylation and re-expression of silenced genes such as glutathione S-transferase P1 (GSTP1). This epigenetic modulation makes it a compound of interest for chemopreventive and therapeutic strategies in cancers driven by DNA hypermethylation.
- Other names
- geraniine
02
Targets
DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)
Beyond the preview
Go deeper on geraniin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on geraniin.